About the Company
We do not have any company description for Entera Bio Ltd. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Entera Bio Ltd.
Entera Bio Announces Full Year 2023 Financial Results and Provides ...
JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial ...
Entera Bio Reports Q3 2023 Financial Results, Highlights ...
JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic ...
Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know ...
Entera Bio Ltd. (ENTX) closed at $1.98 in the latest trading session, marking a -1% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 1.02%.
Entera Bio Ltd. Reports Q1 2025 Financial Results and Business ... - Nasdaq
Entera Bio Ltd. reported its financial results for Q1 2025, highlighting significant advancements in its development of oral peptide therapies, particularly EB613, an oral anabolic treatment for ...
ENTX - Entera Bio Ltd News | Morningstar
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates GlobeNewswire May 9, 2025, 1:05:00 PM ...
ENTX - Entera Bio Ltd Trailing Returns | Morningstar
Stay up to date on how Entera Bio Ltd (ENTX:XNAS) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.
ENTX | Entera Bio Ltd. Annual Income Statement | MarketWatch
Entera Bio Ltd. Annual stock financials by MarketWatch. View the latest ENTX financial statements, income statements and financial ratios.
Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of ...
BOSTON and JERUSALEM, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced financial and ...
Entera Bio Ltd Announces Interim Data From Phase 2 Clinical ... - Nasdaq
--Entera Bio Ltd., a leader in the development of orally delivered large molecule therapeutics, announced financial and operating results for the quarter ended June 30, 2020 as well as 6- month ...
Similar Companies
Loading the latest forecasts...